Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Simoens, Cindy
  • dc.contributor.author Lloveras Rubio, Belen
  • dc.contributor.author Arbyn, Marc
  • dc.contributor.author HPV-AHEAD study group
  • dc.contributor.other Simoens, Cindy; Lloveras Rubio, Belen; Arbyn, Marc; HPV-AHEAD study group
  • dc.date.accessioned 2023-01-18T07:31:04Z
  • dc.date.available 2023-01-18T07:31:04Z
  • dc.date.issued 2022
  • dc.description.abstract Background: the incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. Methods: the accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16(INK4a) immunohistochemistry (IHC) (p16), and (c) the combination of both tests (considering joint DNA and p16 positivity as positivity criterion), was analysed in tissue samples from 99 Belgian OPC patients enrolled in the HPV-AHEAD study. Presence of HPV E6*I mRNA (mRNA) was considered as the reference, indicating HPV etiology. Results: ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. Conclusions: single hrHPV DNA PCR and p16(INK4a) IHC are highly sensitive but less specific than using combined testing to diagnose HPV-driven OPC patients. Disease prognostication can be encouraged based on this combined test result.
  • dc.description.sponsorship The global HPV-AHEAD study was initially funded by the European Commission, with Grant Number: FP7-HEALTH-2011-282562. Sciensano, the employer of CS and MA, received funding for the analysis of the Belgian part of the HPV-AHEAD study, in part, by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. MA was also supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network (Grant No. 847845); and the Belgian Foundation Against Cancer through the IHUVACC project.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Simoens C, Gheit T, Ridder R, Gorbaslieva I, Holzinger D, Lucas E, et al. Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. BMC Infect Dis. 2022 Aug 6; 22(1): 676. DOI: 10.1186/s12879-022-07654-2
  • dc.identifier.doi http://dx.doi.org/10.1186/s12879-022-07654-2
  • dc.identifier.issn 1471-2334
  • dc.identifier.uri http://hdl.handle.net/10230/55318
  • dc.language.iso eng
  • dc.publisher BioMed Central
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/282562
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/847845
  • dc.rights Copyright © Simoens C, Gheit T, Ridder R, Gorbaslieva I, Holzinger D, Lucas E, et al. 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword HPV DNA PCR
  • dc.subject.keyword HPV mRNA
  • dc.subject.keyword HPV-AHEAD
  • dc.subject.keyword Oropharyngeal carcinoma
  • dc.subject.keyword p16(INK4a) IHC
  • dc.subject.keyword Cancer
  • dc.title Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Articles (Departament de Medicina i Ciències de la Vida)